MDCO 700

Drug Profile

MDCO 700

Alternative Names: ABP-700; MDCO 700

Latest Information Update: 17 Aug 2016

Price : $50

At a glance

  • Originator Massachusetts General Hospital
  • Developer The Medicines Company
  • Class Anaesthetics; Esters; Hypnosedatives
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaesthesia

Most Recent Events

  • 27 Jul 2016 The Medicines Company intends to file an IND application with the US FDA
  • 09 May 2016 The Medicines Company plans a phase III trial in Anaesthesia
  • 04 Apr 2016 Phase-II clinical trials in Anaesthesia in Netherlands (IV) (EudraCT2015-004019-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top